Profile data is unavailable for this security.
About the company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-37.58m
- Incorporated2021
- Employees42.00
- LocationSurrozen Inc171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 475-2820
- Fax+1 (302) 655-5049
- Websitehttps://www.surrozen.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rapid Micro Biosystems Inc | 23.10m | -51.90m | 33.75m | 193.00 | -- | 0.3181 | -- | 1.46 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Nuo Therapeutics Inc | 782.01k | -3.02m | 33.83m | -- | -- | 99.51 | -- | 43.26 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 34.13m | 55.00 | -- | 1.14 | -- | 2.01 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Quince Therapeutics Inc | 0.00 | -30.28m | 34.14m | 32.00 | -- | 0.4603 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
NRX Pharmaceuticals Inc | 0.00 | -25.65m | 34.35m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
ImmuCell Corp | 21.28m | -3.90m | 35.08m | 74.00 | -- | 1.41 | -- | 1.65 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Surrozen Inc | 0.00 | -37.58m | 35.47m | 42.00 | -- | 0.7754 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Fortress Biotech Inc | 85.11m | -62.86m | 35.85m | 186.00 | -- | 1.51 | -- | 0.4212 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
Cyclo Therapeutics Inc | 1.13m | -19.39m | 36.06m | 8.00 | -- | 59.10 | -- | 32.01 | -1.03 | -1.03 | 0.0557 | 0.0213 | 0.2001 | 0.4155 | 11.12 | 140,806.30 | -344.43 | -132.22 | -17,225.46 | -215.17 | 91.02 | 90.37 | -1,721.63 | -1,114.04 | 0.968 | -- | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
NKGen Biotech Inc | -100.00bn | -100.00bn | 36.09m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 36.29m | 163.00 | -- | 0.1779 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Benson Hill Inc | 359.83m | -132.72m | 36.55m | 270.00 | -- | 0.5431 | -- | 0.1016 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
OncoCyte Corp | 1.38m | -40.66m | 36.62m | 43.00 | -- | 1.96 | -- | 26.50 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Movano Inc | 852.00k | -27.91m | 36.67m | 30.00 | -- | -- | -- | 43.04 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 04 Apr 2024 | 323.66k | 10.12% |
Euclidean Capital LLCas of 31 Mar 2024 | 87.70k | 2.74% |
Stonepine Capital Management LLCas of 01 Apr 2024 | 64.50k | 2.02% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 61.08k | 1.91% |
ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 55.12k | 1.72% |
Stanford Management Co.as of 31 Mar 2024 | 52.13k | 1.63% |
Columbia Investment Management Co. LLCas of 31 Dec 2023 | 47.93k | 1.50% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 34.88k | 1.09% |
Alyeska Investment Group LPas of 31 Mar 2024 | 20.38k | 0.64% |
Renaissance Technologies LLCas of 31 Mar 2024 | 13.73k | 0.43% |